The combination, known as Bem/Rzr, achieved a 94% sustained virologic response rate, narrowly trailing the 95% efficacy recorded by the comparator treatment. Atea confirmed that the trial successfully met the criteria for statistical non-inferiority, with low and comparable rates of virologic failure observed across all patient populations. Secondary endpoints also aligned with these positive trends, reinforcing the drug's clinical profile.
In section Market Quotes
Atea Pharmaceuticals Reports Success in Hepatitis C Phase 3 Trial
Atea Pharmaceuticals has cleared a critical hurdle for its hepatitis C program, reporting that its combination therapy of bemnifosbuvir and ruzasvir met primary endpoints in a global Phase 3 trial. The results position the company to challenge established treatment regimens by demonstrating competitive efficacy in viral suppression.
Following the announcement, Atea shares rose 1.2% to $4.88 in premarket trading. The company intends to disclose comprehensive data from the global program at upcoming medical conferences, providing a clearer look at the long-term potential of this regimen.
Comments (0)
No comments yet. Be the first!